Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer

por Cardenas, Horacio, Jiang, Guanglong, Thomes Pepin, Jessica, Parker, J. Brandon, Condello, Salvatore, Nephew, Kenneth P., Nakshatri, Harikrishna, Chakravarti, Debabrata, Liu, Yunlong, Matei, Daniela
Publicado 2019

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

por Moore, Kathleen N., Bookman, Michael, Sehouli, Jalid, Miller, Austin, Anderson, Charles, Scambia, Giovanni, Myers, Tashanna, Taskiran, Cagatay, Robison, Katina, Mäenpää, Johanna, Willmott, Lyndsay, Colombo, Nicoletta, Thomes-Pepin, Jessica, Liontos, Michalis, Gold, Michael A., Garcia, Yolanda, Sharma, Sudarshan K., Darus, Christopher J., Aghajanian, Carol, Okamoto, Aikou, Wu, Xiaohua, Safin, Rustem, Wu, Fan, Molinero, Luciana, Maiya, Vidya, Khor, Victor K., Lin, Yvonne G., Pignata, Sandro
Publicado 2021